In ER-positive HER2-negative breast cancer especially, it is recommended to use multi-gene assays, such as Oncotype DX [26], which assess the additional effects of chemotherapy and prognostic predictions based on the intrinsic subtype, to decide on the treatment strategy. This evidence concerns the gene ESR1 and breast carcinoma.